Can PSMA-Targeting Radiopharmaceuticals Be Useful for Detecting Hepatocellular Carcinoma Using Positron Emission Tomography? An Updated Systematic Review and Meta-Analysis

Can PSMA-Targeting Radiopharmaceuticals Be Useful for Detecting Hepatocellular Carcinoma Using Positron Emission Tomography? An Updated Systematic Review and Meta-Analysis

Background: Several studies proposed the use of positron emission tomography (PET) with Prostate-Specific Membrane Antigen (PSMA)-targeting radiopharmaceuticals in hepatocellular carcinoma (HCC). Our aim is to calculate the detection rate (DR) of this examination in HCC with a meta-analysis. Methods...

Full description

Bibliographic Details
Main Authors: Alessio Rizzo, Manuela Racca, Domenico Albano, Francesco Dondi, Francesco Bertagna, Salvatore Annunziata, Giorgio Treglia
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Pharmaceuticals
Subjects:
PSMA
PET
nuclear medicine
liver
hepatocellular carcinoma
oncology
Online Access:https://www.mdpi.com/1424-8247/15/11/1368

Similar Items

Similar Items